88 related articles for article (PubMed ID: 21856552)
1. Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.
García-Sanz R; Ocio E; Caballero A; Magalhães RJ; Alonso J; López-Anglada L; Villaescusa T; Puig N; Hernández JM; Fernández-Calvo J; Aguilar A; Martín A; López R; Paiva B; Orfao A; Vidriales B; San-Miguel JF; Del Carpio D
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):168-71. PubMed ID: 21856552
[TBL] [Abstract][Full Text] [Related]
2. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
3. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.
Ahn A; Park CJ; Cho YU; Jang S; Seo EJ; Lee JH; Yoon DH; Suh C
Ann Lab Med; 2020 May; 40(3):193-200. PubMed ID: 31858758
[TBL] [Abstract][Full Text] [Related]
5. Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.
Owen RG; Barrans SL; Richards SJ; O'Connor SJ; Child JA; Parapia LA; Morgan GJ; Jack AS
Am J Clin Pathol; 2001 Sep; 116(3):420-8. PubMed ID: 11554171
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotypic analysis of Waldenstrom's macroglobulinemia.
San Miguel JF; Vidriales MB; Ocio E; Mateo G; Sánchez-Guijo F; Sánchez ML; Escribano L; Bárez A; Moro MJ; Hernández J; Aguilera C; Cuello R; García-Frade J; López R; Portero J; Orfao A
Semin Oncol; 2003 Apr; 30(2):187-95. PubMed ID: 12720134
[TBL] [Abstract][Full Text] [Related]
7. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells.
Remstein ED; Hanson CA; Kyle RA; Hodnefield JM; Kurtin PJ
Semin Oncol; 2003 Apr; 30(2):182-6. PubMed ID: 12720133
[TBL] [Abstract][Full Text] [Related]
8. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
Treon SP; Kelliher A; Keele B; Frankel S; Emmanouilides C; Kimby E; Schlossman R; Mitsiades N; Mitsiades C; Preffer F; Anderson KC
Semin Oncol; 2003 Apr; 30(2):248-52. PubMed ID: 12720146
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
10. Waldenström's macroglobulinemia: a clinicopathologic study of 22 cases.
Andriko JA; Aguilera NS; Chu WS; Nandedkar MA; Cotelingam JD
Cancer; 1997 Nov; 80(10):1926-35. PubMed ID: 9366295
[TBL] [Abstract][Full Text] [Related]
11. IgM monoclonal gammopathy/Waldenström's macroglobulinemia: a morphological and immunophenotypic study of the bone marrow.
Feiner HD; Rizk CC; Finfer MD; Bannan M; Gottesman SR; Chuba JV; Amorosi E
Mod Pathol; 1990 May; 3(3):348-56. PubMed ID: 2114024
[TBL] [Abstract][Full Text] [Related]
12. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
13. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
14. Developing diagnostic criteria in Waldenstrom's macroglobulinemia.
Owen RG
Semin Oncol; 2003 Apr; 30(2):196-200. PubMed ID: 12720135
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic spectrum of Waldenström's macroglobulinemia: a single center experience.
Sajid R; Siddiqui SH; Shaikh U; Adil S
Indian J Pathol Microbiol; 2010; 53(3):490-3. PubMed ID: 20699509
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
[TBL] [Abstract][Full Text] [Related]
19. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
Kimby E; Treon SP; Anagnostopoulos A; Dimopoulos M; Garcia-Sanz R; Gertz MA; Johnson S; LeBlond V; Fermand JP; Maloney DG; Merlini G; Morel P; Morra E; Nichols G; Ocio EM; Owen R; Stone M; Bladé J
Clin Lymphoma Myeloma; 2006 Mar; 6(5):380-3. PubMed ID: 16640813
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders.
Pangalis GA; Kyrtsonis MC; Kontopidou FN; Vassilakopoulos TP; Siakantaris MP; Dimopoulou MN; Kittas C; Angelopoulou MK
Semin Oncol; 2003 Apr; 30(2):201-5. PubMed ID: 12720136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
